Literature DB >> 29857868

PSA-density does not improve bi-parametric prostate MR detection of prostate cancer in a biopsy naïve patient population.

Renato Cuocolo1, Arnaldo Stanzione1, Giovanni Rusconi1, Mario Petretta2, Andrea Ponsiglione1, Ferdinando Fusco3, Nicola Longo3, Francesco Persico3, Sirio Cocozza1, Arturo Brunetti1, Massimo Imbriaco4.   

Abstract

PURPOSE: Bi-parametric prostate MR (bp-MR) is a valuable tool for detection and characterization of prostate cancer (PCa). Recent studies suggested that PSA-density (PSA-D) in combination with multi-parametric prostate MR as well as bp-MR may achieve a higher diagnostic accuracy than either alone. We aimed to evaluate the diagnostic performance of bp-MR, PSA-D and their combination in biopsy-naïve patients. METHODS AND MATERIALS: We retrospectively analyzed 334 consecutive patients who underwent prostate MR on a 3T scanner. Only patients (n = 114) who underwent TRUS-biopsy within 30 days following MR with no previous prostate biopsies were considered. Our protocol included T2-weighted and DWI sequences. A Likert score based on PI-RADS v2 was used for bp-MR evaluation. Lesions were graded histopathologically using the ISUP score. We assessed three scenarios: detection of lesions independently of ISUP score (ISUP ≥ 1), detection of both intermediate and clinically significant lesions (ISUP ≥ 2) and detection of clinically significant lesions alone (ISUP ≥ 3). Predictive value of bp-MR and PSA-D was evaluated by ROC curves and logistic regression analysis. A p value < 0.05 was considered statistically significant.
RESULTS: In all evaluated scenarios, bp-MR showed a significantly higher predictive power (AUC = 0.87-0.95) compared to the performance of PSA-D (AUC = 0.73-0.79), while their combination (AUC = 0.91-0.95) showed no statistically significant improvement compared to bp-MR alone.
CONCLUSION: Our results confirm that bp-MR is a powerful tool in detection of clinically significant PCa. Contrary to findings in the recent literature, PSA-D does not appear to significantly improve its diagnostic performance.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bi-parametric MR; Biopsy-naïve patients; Prostate cancer; Prostate specific antigen density

Mesh:

Substances:

Year:  2018        PMID: 29857868     DOI: 10.1016/j.ejrad.2018.05.004

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  6 in total

1.  How to implement magnetic resonance imaging before prostate biopsy in clinical practice: nomograms for saving biopsies.

Authors:  Ángel Borque-Fernando; Luis Mariano Esteban; Ana Celma; Sarai Roche; Jacques Planas; Lucas Regis; Inés de Torres; Maria Eugenia Semidey; Enrique Trilla; Juan Morote
Journal:  World J Urol       Date:  2019-09-10       Impact factor: 4.226

Review 2.  Machine learning applications in prostate cancer magnetic resonance imaging.

Authors:  Renato Cuocolo; Maria Brunella Cipullo; Arnaldo Stanzione; Lorenzo Ugga; Valeria Romeo; Leonardo Radice; Arturo Brunetti; Massimo Imbriaco
Journal:  Eur Radiol Exp       Date:  2019-08-07

Review 3.  Active Surveillance of Prostate Cancer Using Multiparametric Magnetic Resonance Imaging: A Review of the Current Role and Future Perspectives.

Authors:  Katarzyna Sklinda; Bartosz Mruk; Jerzy Walecki
Journal:  Med Sci Monit       Date:  2020-04-12

4.  The value of magnetic resonance imaging and ultrasonography (MRI/US)-fusion biopsy in clinically significant prostate cancer detection in patients with biopsy-naïve men according to PSA levels: A propensity score matching analysis.

Authors:  Hye J Byun; Teak J Shin; Wonho Jung; Ji Y Ha; Byung H Kim; Young H Kim
Journal:  Prostate Int       Date:  2021-11-04

5.  Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.

Authors:  Wolfgang M Thaiss; Simone Moser; Tobias Hepp; Stephan Kruck; Steffen Rausch; Marcus Scharpf; Konstantin Nikolaou; Arnulf Stenzl; Jens Bedke; Sascha Kaufmann
Journal:  World J Urol       Date:  2022-08-04       Impact factor: 3.661

6.  Combining prostate-specific antigen density with prostate imaging reporting and data system score version 2.1 to improve detection of clinically significant prostate cancer: A retrospective study.

Authors:  Yin Lei; Tian Jie Li; Peng Gu; Yu Kun Yang; Lei Zhao; Chao Gao; Juan Hu; Xiao Dong Liu
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.